2024-09-04 ワシントン大学セントルイス校
<関連情報>
- https://source.washu.edu/2024/09/adding-anti-clotting-drugs-to-stroke-care-ineffective-clinical-trial-finds/
- https://www.nejm.org/doi/10.1056/NEJMoa2314779
虚血性脳卒中に対するアルガトロバンまたはエプチフィバチドの静脈内併用療法 Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Opeolu Adeoye, M.D., Joseph Broderick, M.D., Colin P. Derdeyn, M.D., James C. Grotta, M.D., William Barsan, M.D., Oladi Bentho, M.D., Scott Berry, Ph.D., +25, and Andrew D. Barreto, M.D.
The New England Journal of Medicine Published: September 4, 2024
DOI: 10.1056/NEJMoa2314779
Abstract
Background
Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide (an antiplatelet agent) are unclear.
Methods
We conducted a phase 3, three-group, adaptive, single-blind, randomized, controlled clinical trial at 57 sites in the United States. Patients with acute ischemic stroke who had received intravenous thrombolysis within 3 hours after symptom onset were assigned to receive intravenous argatroban, eptifibatide, or placebo within 75 minutes after the initiation of thrombolysis. The primary efficacy outcome, the utility-weighted 90-day modified Rankin scale score (range, 0 to 10, with higher scores reflecting better outcomes), was assessed by means of centralized adjudication. The primary safety outcome was symptomatic intracranial hemorrhage within 36 hours after randomization.
Results
A total of 514 patients were assigned to receive argatroban (59 patients), eptifibatide (227 patients), or placebo (228 patients). All the patients received intravenous thrombolysis (70% received alteplase, and 30% received tenecteplase), and 225 patients (44%) underwent endovascular thrombectomy. At 90 days, the mean (±SD) utility-weighted modified Rankin scale scores were 5.2±3.7 with argatroban, 6.3±3.2 with eptifibatide, and 6.8±3.0 with placebo. The posterior probability that argatroban was better than placebo was 0.002 (posterior mean difference in utility-weighted modified Rankin scale score, -1.51±0.51) and that eptifibatide was better than placebo was 0.041 (posterior mean difference, -0.50±0.29). The incidence of symptomatic intracranial hemorrhage was similar in the three groups (4% with argatroban, 3% with eptifibatide, and 2% with placebo). Mortality at 90 days was higher in the argatroban group (24%) and the eptifibatide group (12%) than in the placebo group (8%).
Conclusions
In patients with acute ischemic stroke treated with intravenous thrombolysis within 3 hours after symptom onset, adjunctive treatment with intravenous argatroban or eptifibatide did not reduce poststroke disability and was associated with increased mortality. (Funded by the National Institute of Neurological Disorders and Stroke; MOST ClinicalTrials.gov number, NCT03735979.)
